NCT02811536

Brief Summary

Comparison of OCTA to conventional imaging modalities for the diagnosis of eye diseases

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
440

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2017

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 20, 2016

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 23, 2016

Completed
8 months until next milestone

Study Start

First participant enrolled

February 13, 2017

Completed
5.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 25, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 25, 2022

Completed
Last Updated

November 29, 2022

Status Verified

November 1, 2022

Enrollment Period

5.8 years

First QC Date

June 20, 2016

Last Update Submit

November 28, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Evaluation of the sensitivity and specificity of OCTA

    The primary objective of this observational study is to evaluate the sensitivity and specificity to diagnose vascular abnormalities with OCTA compared to conventional imaging methods. The main parameter that will be assessed is area of nonperfusion of the retina. The incidence (binary) of nonperfusion areas will be assessed in OCTA and compared to conventional imaging methods such as fluorescein angiography.

    2 years

Secondary Outcomes (3)

  • Evaluation of the intra-and inter-reader reproducibility of the diagnosis of vascular abnormalities using OCTA

    2 years

  • OCTA and Fundus color photographs

    2 years

  • Subgroup analysis

    2 years

Study Arms (8)

Diabetic retinopathy

Patients with various degrees of diabetic retinopathy

Device: optical coherence tomography angiography

Retinal detachment

Patients with a history of retinal detachment

Device: optical coherence tomography angiography

Retinal vein occlusion

Patients with a history of retinal vein occlusion

Device: optical coherence tomography angiography

Arterial hypertension

Patients with a history of arterial hypertension

Device: optical coherence tomography angiography

Carotid artery occlusion

Patients with a history of carotid artery occlusion

Device: optical coherence tomography angiography

Age related macular degeneration

Patients with a history of Age related macular degeneration

Device: optical coherence tomography angiography

Macroaneurysms

Patients with a history of retinal macroaneurysms

Device: optical coherence tomography angiography

Central serous chorioretinopathy

Patients with a history of central serous chorioretinopathy

Device: optical coherence tomography angiography

Interventions

Imaging with optical coherence tomography angiography

Age related macular degenerationArterial hypertensionCarotid artery occlusionCentral serous chorioretinopathyDiabetic retinopathyMacroaneurysmsRetinal detachmentRetinal vein occlusion

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Participants with a history of clinically diagnosed retinal diseases, including but not limited to age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, macular macroaneurysma, and diabetic macular edema and healthy individuals undergoing ophthalmic Imaging in Routine clinical practice will be included

You may qualify if:

  • Patients from the Department of Ophthalmology, University Hospital Bern requiring conventional imaging for eye disease and willing to sign informed consent Patients of 18 years or older

You may not qualify if:

  • Patients not willing or able to sign informed consent Patients younger than 18 years Patients with epilepsy Patients having had photodynamic therapy within the last 48 hours prior to imaging with OCTA

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Inselspital Bern, Department of Ophthalmology

Bern, 3010, Switzerland

Location

Related Publications (2)

  • Tian M, Zeng G, Zinkernagel M, Tappeiner C, Wolf S, Munk MR. Assessment of choriocapillaris and choroidal vascular changes in posterior uveitis using swept-source wide-field optical coherence tomography angiography. Br J Ophthalmol. 2024 Feb 21;108(3):386-390. doi: 10.1136/bjo-2022-322209.

  • Tian M, Tappeiner C, Zinkernagel MS, Huf W, Wolf S, Munk MR. Evaluation of vascular changes in intermediate uveitis and retinal vasculitis using swept-source wide-field optical coherence tomography angiography. Br J Ophthalmol. 2019 Sep;103(9):1289-1295. doi: 10.1136/bjophthalmol-2018-313078. Epub 2018 Dec 11.

MeSH Terms

Conditions

Retinal Diseases

Condition Hierarchy (Ancestors)

Eye Diseases

Study Officials

  • Martin Zinkernagel, Prof.MD PhD

    Inselspital, University Clinic for Ophthalmology

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 20, 2016

First Posted

June 23, 2016

Study Start

February 13, 2017

Primary Completion

November 25, 2022

Study Completion

November 25, 2022

Last Updated

November 29, 2022

Record last verified: 2022-11

Data Sharing

IPD Sharing
Will not share

Locations